08:59 AM EDT, 08/19/2024 (MT Newswires) -- Alzamend Neuro ( ALZN ) said Monday it is teaming up with Massachusetts General Hospital for a phase II clinical trial of its lithium therapeutic drug candidate for post-traumatic stress disorder.

The study of AL001 aims to compare the increase in lithium levels within the brain and its structures versus a commonly marketed lithium salt among PTSD patients to predict the needed minimum dose to achieve the equivalent effectiveness and safety of AL001, the company said.

The company said it identified a maximum tolerated dose for the development of AL001 in a previously completed phase IIa multiple ascending dose clinical trial.

Shares of Alzamend soared 208% in premarket activity.

Price: 6.1200, Change: +4.09, Percent Change: +201.48